Lilly Demo
Patient Journey Demonstration

Meet Maia

A representative patient navigating the path to Zepbound® using Teleport Health.

Maia Hernandez
47 • Austin, TX • Mother of two
BMI 34Prediabetes (A1c 6.2%)HypertensionHyperlipidemia (LDL elevated)
Medical records connected  · 211 records via MyChart
Before Teleport
Understand coverage and costs
Complete prior authorization
Find medication availability
Coordinate care
With Teleport
Connect medical records securely
Find out if treatment is right for you
Navigate insurance requirements
Get your medication to a pharmacy near you
Support treatment initiation
Stay engaged through treatment

Follow Maia's treatment journey and see how Teleport supports patients — from qualifying and getting covered to starting treatment and staying on track.

Maia is a fictional persona. Zepbound® is a registered trademark of Eli Lilly and Company.

Illustrative / internal review only — not promotional. Includes named-drug references for demo purposes.

Morning, Maia 👋

FindingsSee all
Insurance renewal due Mar 30

Your renewal paperwork is ready. It shows your 15% weight loss and on-time doses. Teleport can submit it today.

Dose decision ahead

Dr. Rao suggested stepping up to 10 mg. Your visit guide compares moving up vs. staying at your dose — and how to handle side effects either way.

ActionsSee all
Insurance renewalZepbound® coverageDrafted
Next: Review and senddue Mar 30
Pharmacy refillZepbound® 7.5 mg · titration stepProcessing
Next: Savings card applied at fillships Fri
Visit prepDr. Rao · telehealth Apr 14, 3:00 PMReady
Next: Your visit guide is ready — 3 questions to ask1–2 min read
Quick accessSee all
Care team
Health records
Medications
Appointments
Coverage
Injection guide
Illustrative / internal review only — not promotional
Maia's GLP-1 story
choose to begin →

Maia's GLP-1 journey

9 steps · your choices fill this in
Maia Hernandez's Twin
92%
Open Maia's health records
211 FHIR resources · twin 92% complete
Health records
Maia Hernandez
47y · female  # W2738461902
4
CONDITIONS
3
MEDICATIONS
2
ALLERGIES
Clinical Narrative

47-year-old with obesity and prediabetes, 4 months into tirzepatide (7.5 mg titration hold). Down 30 lb (BMI 34→29), A1c 6.2→5.6%.

MOST PRESSING NEXT ACTION
GLP-1 Re-Authorization due Mar 30
Illustrative / internal review only — not promotional. Includes named-drug references for demo purposes.